In the current study, we confirmed a direct role of the complement component C3 in the pathophysiological process of PAH and found that CP40-KK, a new analog of selective C3 inhibitor CP40, could protect against the established PAH in the MCT-induced rat model. Here, C3 is linked to pulmonary arterial hypertension.